UBS initiated coverage of Rohto Pharmaceutical (RPHCF) with a Neutral rating and 2,600 yen price target The firm sees a balanced risk/reward at the stock’s current valuation, noting the company’s core business growth has slowed.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPHCF:
- Rohto Pharmaceutical Reports Strong Growth in Latest Earnings
- Rohto Pharmaceutical Acquires OBAGI Trademarks in Japan
- Rohto Pharmaceutical Revises Earnings and Dividend Forecasts Upward
- Rohto Pharmaceutical Reports Strong Financial Growth and Strategic Expansion
- Rohto Pharmaceutical’s New Study: A Potential Game-Changer for Heart Disease Treatment?